Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Tadekinig alfa by AB2 Bio for Hemophagocytic Lymphohistiocytosis: Likelihood of Approval
Tadekinig alfa is under clinical development by AB2 Bio and currently in Phase III for Hemophagocytic Lymphohistiocytosis. According to GlobalData,...
Data Insights
Tadekinig alfa by AB2 Bio for Lymphoproliferative Disorders: Likelihood of Approval
Tadekinig alfa is under clinical development by AB2 Bio and currently in Phase III for Lymphoproliferative Disorders. According to GlobalData,...